FMS Stock Recent News
FMS LATEST HEADLINES
Fresenius Medical Care has been a long-term laggard in its industry, losing over 70% in the past 5 years. The stock has seemingly bottomed and began to retrace on massive buy-side volume while breaking out of one of its most important short-term resistance.
Fresenius Medical (FMS) continues to gain traction through its broad dialysis product and service portfolio. Intense competition is a woe.
Fresenius Medical's (FMS) second-quarter earnings benefit from strong performance across all the geographic regions and segments. However, rising costs hurt margins.
Fresenius isn't just an undervalued aristocrat, it's a Buffett-style anti-bubble "fat pitch" that could deliver 235% returns in the next five years. Even with the Pandemic-induced downturn, FMS is expected to grow at 12% CAGR through 2027.
Shares of Fresenius Medical Care tumbled 13.7% in premarket trading on Thursday after telling investors to expect lower-than-expected revenue and net income in the second half of the year. The company, which provides kidney dialysis services, cited concerns about wage inflation and staff shortages in North America, higher inflation, and supply-chain disruptions.
The heavy selling pressure might have exhausted for Fresenius (FMS) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Fresenius Medical (FMS) continues to gain traction through its broad dialysis product and service portfolio. Intense competition is a woe.
The Department of Justice of the U.S. government files a civil complaint against Fresenius (FMS), accusing it of defrauding Medicare and other healthcare programs by billing for unnecessary procedures.
We'll take a look at Fresenius in order to determine if the company still represents a good investment opportunity. Given a recent share price weakness, it's not strange that some investors are wondering whether it's still investable.
Fresenius Medical (FMS) continues to gain traction through its broad dialysis product and service portfolio. Intense competition is a woe.